Tags

Type your tag names separated by a space and hit enter

Disease modifying therapies for relapsing multiple sclerosis.
BMJ 2016; 354:i3518BMJ

Abstract

Multiple sclerosis (MS) is a common, disabling, putatively autoimmune neurological disease with worldwide distribution. It typically begins as a relapsing disorder that later evolves to a secondary progressive phase. Inflammatory and neurodegenerative mechanisms seem to operate in both phases, but their relative contributions and interactions are incompletely understood. Disease modifying therapies (DMTs) approved for relapsing multiple sclerosis interfere with a variety of immunological mechanisms to reduce rates of relapse, accumulation of disease burden measured by magnetic resonance imaging (MRI), and decline in neurological function over the two to three year duration of typical randomized controlled trials. Benefits of longer duration of therapy on disability are less clear, as data beyond three years are largely limited to observational studies. However, current DMTs do not slow accrual of disability once progressive multiple sclerosis is established. This review summarizes the evidence about the use of approved DMTs and examines how to individualize treatment despite the absence of validated biomarkers to guide drug selection. Methods such as stratifying patients on the basis of estimated risk for future disability, weighing patient specific factors and preferences, and using objective outcomes to adjudicate treatment success are discussed. Emerging drug therapies and strategies are also reviewed.

Authors+Show Affiliations

Department of Neurology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ, 85259, USA wingerchuk.dean@mayo.edu.Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27549763

Citation

Wingerchuk, Dean M., and Brian G. Weinshenker. "Disease Modifying Therapies for Relapsing Multiple Sclerosis." BMJ (Clinical Research Ed.), vol. 354, 2016, p. i3518.
Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ. 2016;354:i3518.
Wingerchuk, D. M., & Weinshenker, B. G. (2016). Disease modifying therapies for relapsing multiple sclerosis. BMJ (Clinical Research Ed.), 354, p. i3518. doi:10.1136/bmj.i3518.
Wingerchuk DM, Weinshenker BG. Disease Modifying Therapies for Relapsing Multiple Sclerosis. BMJ. 2016 Aug 22;354:i3518. PubMed PMID: 27549763.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Disease modifying therapies for relapsing multiple sclerosis. AU - Wingerchuk,Dean M, AU - Weinshenker,Brian G, Y1 - 2016/08/22/ PY - 2016/8/24/entrez PY - 2016/8/24/pubmed PY - 2017/3/23/medline SP - i3518 EP - i3518 JF - BMJ (Clinical research ed.) JO - BMJ VL - 354 N2 - Multiple sclerosis (MS) is a common, disabling, putatively autoimmune neurological disease with worldwide distribution. It typically begins as a relapsing disorder that later evolves to a secondary progressive phase. Inflammatory and neurodegenerative mechanisms seem to operate in both phases, but their relative contributions and interactions are incompletely understood. Disease modifying therapies (DMTs) approved for relapsing multiple sclerosis interfere with a variety of immunological mechanisms to reduce rates of relapse, accumulation of disease burden measured by magnetic resonance imaging (MRI), and decline in neurological function over the two to three year duration of typical randomized controlled trials. Benefits of longer duration of therapy on disability are less clear, as data beyond three years are largely limited to observational studies. However, current DMTs do not slow accrual of disability once progressive multiple sclerosis is established. This review summarizes the evidence about the use of approved DMTs and examines how to individualize treatment despite the absence of validated biomarkers to guide drug selection. Methods such as stratifying patients on the basis of estimated risk for future disability, weighing patient specific factors and preferences, and using objective outcomes to adjudicate treatment success are discussed. Emerging drug therapies and strategies are also reviewed. SN - 1756-1833 UR - https://www.unboundmedicine.com/medline/citation/27549763/Disease_modifying_therapies_for_relapsing_multiple_sclerosis_ L2 - http://www.bmj.com/cgi/pmidlookup?view=long&pmid=27549763 DB - PRIME DP - Unbound Medicine ER -